Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Firms May Lose Data Exclusivity Earlier Under Planned EU Adaptive Licensing Regime

This article was originally published in The Pink Sheet Daily

Executive Summary

Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.

Advertisement

Related Content

Cancer Drug Cull By NHS Sparks Demands For NICE Reform
Adapting HTA To A Value-Based Approach: A Conversation With ABPI's Stephen Whitehead
Europe Unveils New Health Commissioner And Restructuring For Growth
European Notebook: Industry’s Post-EU Election Goals; IMI2 Gets Under Way; FDA/EMA Tie-Up On Childhood Gaucher Studies
“Adaptive Licensing” Proposals View REMS As Answer To Limited Evidence
Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel